Clinical trials: Substance-Induced Psychoses
Schizophrenia, Dual Diagnosis
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients…
- Conditions
- Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
- Trial name
- NCT01964404
- Testing
- Marijuana, Dronabinol
- Where
- 2 sites in United States
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Dual Diagnosis
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
Many individuals with schizophrenia also suffer from marijuana addiction. Clozapine, an atypical antipsychotic medication, may prove useful at preventing drug relapse in schizophrenic individuals who are seeking treatment for…
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00498550
- Testing
- Clozapine, Treatment as usual
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
The proposed study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
- Trial name
- NCT03526354
- Testing
- Brexpiprazole, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Massachusetts, Worcester
Bipolar Disorder, Alcoholism
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
The investigators will conduct a 12-week, randomized, double-blind, parallel-group, placebo-controlled study of aripiprazole in 132 persons with Alcohol Use Disorder (AUD) and bipolar I or II disorder, currently depressed or…
- Conditions
- Bipolar Disorder, Alcoholism, Alcohol Abuse
- Trial name
- NCT02918370
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Tobacco Dependence, Schizophrenia
Cigarette Smoking in Smokers With and Without Schizophrenia
Higher rates and severity of tobacco dependence in people with schizophrenia, as compared with the general population, contribute to the lower life expectancy seen in this population.
- Trial name
- NCT04001114
- Testing
- Sampling Research Cigarettes
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Bipolar Disorder
Individualizing Incentives for Alcohol in the Severely Mentally Ill
The investigators will evaluate the efficacy of a 2 various contingency management (CM) interventions (High-Magnitude CM, Shaping CM) for treating heavy drinking among individuals with serious mental illness and alcohol…
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Alcohol Dependence
- Trial name
- NCT03481049
- Testing
- Usual CM, High-Magnitude CM, Shaping CM
- Where
- 2 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Washington State University
Cannabis-Related Disorder, Substance-Related Disorders
First Episode Schizophrenia and Cannabis-Related Disorder Study
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response.
- Conditions
- Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00573287
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Alcohol Use Disorder
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).
- Trial name
- NCT02161718
- Testing
- Samidorphan + olanzapine (ALKS 3831)
- Where
- 71 sites in United States, Bulgaria and 1 more
- Volunteers
- 300 people
- Sponsor
- Alkermes, Inc.
Smoking Cessation, Nicotine Addiction
Circuitry-Guided Smoking Cessation in Schizophrenia
In a double-blinded, randomized, parallel controlled design, patients with schizophrenia spectrum disorder will be exposed to active or sham repetitive transcranial magentic stimulation (TMS) which was guided by functional…
- Conditions
- Smoking Cessation, Nicotine Addiction, Schizophrenia
- Trial name
- NCT03281629
- Testing
- Active TMS stimulation
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Maryland, Baltimore
Psychosis, Substance Abuse
Effect Evaluation of Individual Placement and Support (IPS)
Roughly one third of disability pensions issued in Norway are classified as mental and behavioral disorders. The proposed study aims to evaluate the effect of an innovative intervention for returning people with moderate to…
- Conditions
- Psychosis, Substance Abuse, Depression, Anxiety
- Trial name
- NCT01964092
- Testing
- Individual Placement and Support, Ordinary employment schemes
- Where
- Norway
- Volunteers
- 410 people
- Sponsor
- NORCE Norwegian Research Centre AS
Schizophrenia, Tobacco Use Disorder
Varenicline Effects In Schizophrenic Smokers
This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3)…
- Conditions
- Schizophrenia, Tobacco Use Disorder, Nicotine Dependance
- Trial name
- NCT00548470
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Alcohol Abuse, Schizophrenia
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
The investigators will evaluate the efficacy of a comprehensive 12-week contingency management intervention for treating alcohol dependence for persons with severe mental illness who are seen within the context of a community…
- Conditions
- Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- CMETG (NCT01567943)
- Testing
- Contingency Management
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Washington
Substance-Related Disorders, Mental Disorder
Community Health Worker Training to Reduce Depression and Substance Use Stigma in TB/HIV Care in South Africa
Poor engagement in care contributes to HIV- and TB-related morbidity and mortality in South Africa (SA). Community health workers (CHWs) are frontline lay health workers who work to re-engage patients who are lost to follow-up…
- Conditions
- Substance-Related Disorders, Mental Disorder, Social Stigma, Depression
- Trial name
- Siyakhana (NCT05282173)
- Testing
- Siyakhana CHW Training
- Where
- South Africa
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Bipolar Disorder, Schizophrenia
Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness
Approximately 60 chronic smokers with bipolar disorder, schizophrenia or schizoaffective disorder who are motivated to try to quit smoking will be randomized to receive smoking cessation treatment with the FDA-approved…
- Conditions
- Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Nicotine Dependence
- Trial name
- NCT04011280
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of California, San Diego
Tobacco Use, Tobacco Smoking
Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)
Due to the pandemic, this study was modified from a randomized clinical trial to test the feasibility, initial efficacy, and mechanisms of action of our PTSC-S intervention to a feasibility and acceptability test of our…
- Conditions
- Tobacco Use, Tobacco Smoking, Tobacco Use Cessation, Tobacco Use Disorder
- Trial name
- PTSC-S (NCT03873337)
- Testing
- Persistence Targeted Smoking Cessation in SMI (PTSC-S), Nicotine patch
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Rutgers, The State University of New Jersey
HIV Infections, Schizophrenia
Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
This study will determine the effectiveness of the STIRR (Screen, Test, Immunize, Reduce risk, and Refer) intervention in increasing rates of testing, immunization, referral, and treatment for blood-borne diseases, such as…
- Conditions
- HIV Infections, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00316303
- Testing
- Twinrix, Enhanced treatment as usual
- Where
- United States
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Alcohol Dependence, Schizophrenia
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
The aim of this study is to evaluate the safety and efficacy of acamprosate for patients with alcohol dependence and comorbid schizophrenia spectrum disorders.
- Trial name
- NCT00463346
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Alcoholism, Schizophrenia
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia.
- Trial name
- NCT00338598
- Testing
- Glycine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse
- Trial name
- NCT00156715
- Testing
- Quetiapine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Tobacco Use Disorder, Schizophrenia
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
The objective of this study is to investigate the relative contributions of nicotine replacement and sensorimotor replacement (i.e., smoking denicotinized cigarettes) on abstinence-induced smoking urges, withdrawal-related…
- Trial name
- NCT01213524
- Testing
- sensorimotor replacement, 42 mg transdermal nicotine replacement, usual brand smoking
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Brown University